Results 241 to 250 of about 138,235 (308)

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. [PDF]

Clin Cancer Res
Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR.   +18 more
europepmc   +1 more source

Lymphoma, multiple myeloma and leukaemia incidence in regions of Belarus most heavily contaminated by the Chernobyl accident

International Journal of Cancer, Volume 158, Issue 12, Page 3161-3172, 15 June 2026.
What's new? The 1986 Chernobyl accident led to widespread radioactive contamination across parts of Europe, with elevated childhood leukaemia rates observed in heavily affected areas of Ukraine. Data on long‐term haematological and other non‐thyroid cancer risk in the general population in heavily contaminated regions, however, remain limited.
Ljubica Zupunski, Alesia Yaumenenka, Ilya Veyalkin, Victor Minenko, Pavel Moiseyev, Joachim Schüz, Tatiana Kukhta, Sergey Trofimik, Richard Harbron, Vladimir Drozdovitch, Evgenia Ostroumova   +10 more
wiley   +1 more source

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL). [PDF]

Clin Cancer Res
Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML.   +20 more
europepmc   +1 more source

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

American Journal of Hematology, Volume 101, Issue 6, Page 1388-1397, June 2026.
ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana, Hikaru Hayashi, Bethany Thach, Zhi Zhang Yang, Brianna J. Negaard, James R. Cerhan, Anne J. Novak, Brian K. Link, Thomas M. Habermann, Andrew L. Feldman, Sameer A. Parikh, Susan L. Slager, Stephen M. Ansell, Matthew J. Maurer, Denise L. Faustman   +14 more
wiley   +1 more source

The Atypical and Suspicious for Malignancy Categories of the WHO Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Review of their Diagnostic Utility, Limitations, and Clinical Impact

Diagnostic Cytopathology, Volume 54, Issue 6, Page 449-460, June 2026.
ABSTRACT Background Fine‐needle aspiration biopsy (FNAB) is the preferred first‐line diagnostic tool for evaluating lymphadenopathy due to its minimally invasive nature and cost‐effectiveness. However, cytopathological interpretation of lymph node FNAB remains challenging because of the wide morphological spectrum of lymphoid lesions.
Immacolata Cozzolino, Mats Ehinger, Oscar Lin, Elisabetta Maffei, Pio Zeppa, Andrew S. Field   +5 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. [PDF]

Cancer Sci
Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K.   +7 more
europepmc   +1 more source

Understanding the decision of parents to opt‐out of medically actionable secondary findings offered through genome sequencing

Journal of Genetic Counseling, Volume 35, Issue 3, June 2026.
Abstract Genomic sequencing (GS) for patients and families with rare disease creates the opportunity for precise diagnosis as well as the option to learn about medically actionable secondary findings (SF). Debate persists internationally on how to manage the analysis and disclosure of SF, especially in settings where service delivery models for GS are ...
Abigail Hansen, Stephanie Luca, Olivia Moran, Riyana Babul‐Hirji, Teresa B. Coe, Kalin Wilk, Daniel Assamad, Katharine Fooks, Viji Venkataramanan, Salma Shickh, Joyce Yan, Vercancy Wu, Lauren Badalato, Tugce B. Balci, Virginie Beausejour Ladouceur, Lauren Chad, Caitlin Chisholm, Meredith K. Gillespie, Lijia Huang, Olga Jarinova, Lynette Lau, Whiwon Lee, Michael P. Mackley, Christian R. Marshall, Roberto Mendoza‐Londono, Chantal F. Morel, Julie Richer, Sarah Sawyer, Dimitrios James Stavropoulos, Anna Szuto, Mark Tarnopolsky, Anita Villani, Laura Zahavich, Martin J. Somerville, Kym M. Boycott, Wendy J. Ungar, Robin Z. Hayeems   +36 more
wiley   +1 more source

HIV infection complicated with talaromyces marneffei, tuberculosis, hemophagocytic lymphohistiocytosis and non-Hodgkin lymphoma: a complex case report. [PDF]

BMC Infect Dis
Fu W, Deng ZW, Wang P, Zhu ZW, Xie ZB, Li YZ, Zhang HQ, Yu HY.   +7 more
europepmc   +1 more source

Effect of blueberry extract on enhancement of radiosensitivity in non-Hodgkin lymphoma by modulating proliferation and apoptosis. [PDF]

Daru
Moradloo N, Arab S, Jam HR, Asgharzadeh S, Shokri S, Nasehi L, Nokhodchi A.   +6 more
europepmc   +1 more source

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank. [PDF]

Case Rep Oncol Med
Abboushi MB, Marouf O, AbuBaha M, Salameh H, Soradi R, Amer RA.   +5 more
europepmc   +1 more source